T-DM1 Improves OS vs Trastuzumab in Breast Cancer Patients With Residual Disease

Updated results from the KATHERINE trial suggest that T-DM1 can improve OS when compared to trastuzumab in patients with HER2+ early breast cancer who have residual invasive disease after neoadjuvant therapy. T-DM1 can improve OS when compared to trastuzumab in patients with HER2+ early breast cancer who have residual invasive disease after neoadjuvant therapy.

Related Keywords

Germany ,San Antonio ,Texas ,United States ,German ,Ascentage Pharma ,Daiichi Sankyo ,Genentech Roche ,German Breast Group In Neu Isenburg ,Astrazeneca ,Novartis ,Pfizer ,Sibylle Loibl ,German Breast Group ,Clinical Trials Identifier ,San Antonio Breast Cancer Symposium ,Seattle Genetics ,